Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for babies with severe epilepsy: drug trial targets dravet syndrome

NCT ID NCT06118255

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times

Summary

This study tests the safety of fenfluramine in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The medicine is given daily alongside other seizure drugs to help control seizures. The goal is to see if it is safe and well-tolerated in this young age group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ep0213 103

    Seattle, Washington, 98105, United States

  • Ep0213 105

    Memphis, Tennessee, 38103-2800, United States

  • Ep0213 107

    Dallas, Texas, 75207, United States

  • Ep0213 201

    Roma, Italy

  • Ep0213 202

    Florence, Italy

  • Ep0213 203

    Genova, Italy

  • Ep0213 204

    Roma, Italy

  • Ep0213 303

    Bielefeld, Germany

  • Ep0213 401

    London, United Kingdom

  • Ep0213 403

    Glasgow, United Kingdom

  • Ep0213 501

    Edegem, Belgium

  • Ep0213 502

    Brussels, Belgium

Conditions

Explore the condition pages connected to this study.